2 citations
,
August 2021 in “Photodiagnosis and Photodynamic Therapy” Using 5-aminolevulinic acid photodynamic therapy for hair loss didn't increase hair growth but slightly reduced scalp oiliness, and it was safe with mild side effects.
10 citations
,
August 2024 in “Chemical Engineering Journal” The ATAN-Met hydrogel helps heal infected diabetic wounds by promoting tissue regeneration and fighting bacteria.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
3 citations
,
June 2020 in “Journal of Dermatological Treatment” Triamcinolone acetonide is slightly more effective than betamethasone for hair regrowth in localized alopecia areata.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
March 2024 in “Bioactive Materials” New treatment using engineered nanovesicles in hydrogel improves hair growth by repairing hair follicle cells in a mouse model of hair loss.
6 citations
,
May 2021 in “Journal of Health Sciences” Intravenous delivery of autologous activated platelet-rich plasma is safe.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
Topical GT20029 effectively promotes hair regrowth and is well-tolerated.
2 citations
,
October 2025 in “Frontiers in Medicine” Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
Combining epinephrine with a steroid may help regrow hair in severe alopecia areata cases.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
January 2026 in “International Society of Hair Restoration Surgery” Tattoo machine-assisted drug delivery may improve hair growth in androgenetic alopecia.
December 2023 in “International journal of research in dermatology” Adding PRP to topical mometasone improves and speeds up alopecia areata treatment.
6 citations
,
October 2016 in “Pediatric Dermatology” A 6-year-old girl had a rare allergic reaction to a hair regrowth treatment.
5 citations
,
January 2020 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” Injecting platelet-rich plasma or applying it with a laser or microneedling can treat hair loss effectively. The laser and microneedling methods cause less pain.
February 2023 in “Materials today bio” The treatment effectively promotes hair regrowth in androgenetic alopecia without causing skin irritation.
October 2025 in “Clinical Case Reports” PRP injection for hair growth can cause reversible vision loss due to inflammatory optic neuropathy.
July 2023 in “Clinical dermatology review” Intralesional triamcinolone acetonide is better than PRP for treating scalp alopecia areata, leading to faster and more complete hair regrowth.
4 citations
,
March 2016 in “Dermatologic Surgery” PRP treatment increased hair density, especially in men and younger patients with AGA.
1 citations
,
August 2022 in “Frontiers in Medicine” ALRV5XR effectively promotes hair regrowth in both men and women through different mechanisms.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
3 citations
,
January 2018 in “Rawal Medical Journal” Intralesional triamcinolone acetonide via Dermojet is highly effective for treating alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.